List view / Grid view
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
Scientists have developed a drug-like molecule to target amyloid-beta, a disordered protein implicated in Alzheimer's disease that has been considered undruggable.
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
Researchers have mapped 90 percent of the human proteome, which could inform the development of new medicines.
Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.
Researchers suggest that targeting host proteins with drugs, rather than directly targeting enzymes or proteins on SARS-CoV-2 and related coronaviruses, could improve outcomes.
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
A team has identified 219 molecules and genes that influence the severity of COVID-19 in patients, providing information that could aid the development of therapeutics.
![Wasp on a wooden platform [Credit: University of Pennsylvania].](https://www.drugtargetreview.com/wp-content/uploads/Vespula-lewisii-wasp-750x500.jpg)
![Wasp on a wooden platform [Credit: University of Pennsylvania].](https://www.drugtargetreview.com/wp-content/uploads/Vespula-lewisii-wasp-e1602594547599.jpg)
Altering the mastoparan-L (mast-L) peptide found in Vespula lewisii wasp venom, researchers created several novel antimicrobial molecules.
The team demonstrated that expression of Bach2 protein and reduced mTORC1 activity is necessary for germinal B cells to become memory B cells.
A common SARS-CoV-2 mutation known as D614G should not impact on the efficacy of COVID-19 vaccines, a study has shown.
